Preparation of a therapeutic composition
AssigneeAdvanced Viral Research Corp.
InventorsBernard Friedland, Shalom Z. Hirschman, Irach B. Taraporewala
Life of this patent
Estimating the term…
Abstract
Product R, a novel therapeutic composition for treating viral infections and stimulating the immune system, comprises a unique peptide having 31 amino acids and another unique peptide having 21 amino acids and connected with an oligo-nucleotide through a diphosphodiester or diphosphodithioate ester linkage. The composition has a light absorption spectrum with typical absorption ratios of 1.998 at 260 nm/280 nm and 1.359 at 260 nm/230 nm.
Claims38
A peptide of SEQ ID NO:
- 1.
A nucleotide-peptide, comprising a peptide of SEQ ID NO:
- 2 and a nucleotide connected to said peptide, said nucleotide-peptide is represented by the following formula:
- 1
- wherein R1 and R2 are hydrogen, alkyl, arylalkyl, hereroacryl or aryl;
- X is oxygen or sulfur;
- Y is hydrogen, hydroxyl group or halogen;
- B is purine or pyrimidine;
- and n is from zero to 10,000.
A nucleotide-peptide, comprising a peptide having a hydroxylated amino acid residue, and a nucleotide having a diphosphodiester moiety, wherein said peptide is covalently connected to said nucleotide at the hydroxyl group of said hydroxylated amino acid residue through said diphophodiester.
A pharmaceutical composition, comprising a peptide of SEQ ID NO:
- 1.
A pharmaceutical composition, comprising a nucleotide-peptide, said nucleotide-peptide comprising a peptide having a serine residue, and a nucleotide having a diphosphodiester moiety, wherein said peptide is covalently connected to said nucleotide at the hydroxyl group of said serine residue through said diphophodiester.
A pharmaceutical composition, comprising a nucteotide-peptide which comprises a peptide of SEQ ID NO:
- 2 and a nucleotide connected to said peptide, said nucleotide-peptide is represented by the following formula:
- 2
- wherein R1 and R2 are Hydrogen, alkyl, arylalkyl, hereroacryl or aryl;
- X is oxygen or sulfur;
- Y is hydrogen, hydroxyl group or halogen;
- B is purine or pyrimidine;
- and n is from zero to 10,000.
A pharmaceutical composition, comprising a peptide having about 31 amino acids and being capable of stimulating the production of interlukin-8 in cultured cells.
A pharmaceutical composition, comprising a nticleotide-peptide having a serine residue and a dinucleotide moiety, said nucleotide-peptide residue being capable of stimulating the production of interlukin-8 in cultured cells.
A pharmaceutical composition, comprising a peptide having about 31 amino acids and being capable of stimulating the production of monocyte chemotactic protien 1 in cultured cells.
A pharmaceutical composition, comprising nucleotide-peptide having a serine residue and a dinucleotide moiety, said nucleotide-peptide residue being capable of stimulating the production of interlukin-8 in cultured cells.
A pharmaceutical composition, comprising a peptide nucleic acid preparation that absorbs light at wavelengths 230 nm, 260 nm and 280 nm so as to result in 260 nm/280 nm absorption ratio of about 1.998 and 260 nm/230 nm absorption ratio of about 1.359, comprising molecules of nucleotides resulting from a plant RNA and peptides resulting from a mixture of casein, beef peptone and bovine serum albumin, said molecules having non-uniformly distributed molecular weights.
Dependencies are inferred from the claim text.